Jacobs Levy Equity Management’s Pacira BioSciences PCRX Stock Holding History

Jacobs Levy Equity Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.07M	Buy	199,800 +11,614	+6%	+$275K	0.02%	428
2026 Q1	$4.25M	Buy	188,186 +17,711	+10%	+$394K	0.02%	449
2025 Q4	$4.41M	Sell	170,475 -482,105	-74%	-$11.5M	0.02%	433
2025 Q3	$16.8M	Sell	652,580 -332,162	-34%	-$8.16M	0.07%	223
2025 Q2	$23.5M	Buy	984,742 +129,254	+15%	+$3.26M	0.09%	195
2025 Q1	$21.3M	Buy	855,488 +401,227	+88%	+$9.61M	0.08%	217
2024 Q4	$8.56M	Buy	+454,261	New	+$7.98M	0.03%	327
2021 Q1	–	Sell	-55,041	Closed	-$3.29M	–	1098
2020 Q4	$3.29M	Sell	55,041 -4,723	-8%	-$277K	0.03%	476
2020 Q3	$3.59M	Sell	59,764 -162,531	-73%	-$9.44M	0.04%	415
2020 Q2	$11.7M	Sell	222,295 -20,882	-9%	-$873K	0.13%	189
2020 Q1	$8.15M	Buy	243,177 +418	+0.2%	+$17.4K	0.1%	209
2019 Q4	$11M	Buy	242,759 +46,660	+24%	+$1.98M	0.11%	225
2019 Q3	$7.46M	Buy	196,099 +12,000	+7%	+$479K	0.09%	263
2019 Q2	$8.01M	Buy	184,099 +13,660	+8%	+$580K	0.11%	244
2019 Q1	$6.49M	Buy	170,439 +71,150	+72%	+$2.78M	0.09%	282
2018 Q4	$4.27M	Buy	+99,289	New	+$4.63M	0.08%	297
2017 Q4	–	Sell	-7,280	Closed	-$273K	–	1046
2017 Q3	$273K	Buy	+7,280	New	+$293K	0.01%	806

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jacobs Levy Equity Management's PCRX Position: Q2 2026 in Review

Jacobs Levy Equity Management increased its Pacira BioSciences (PCRX) stake by 6.2% in Q2 2026, buying an estimated $275K and bringing the position to 199,800 shares worth $5.07M. The position accounts for 0.02% of the portfolio, ranked #428.

Jacobs Levy Equity Management first reported a position in PCRX in Q3 2017 and has held it in 17 quarters since. The position peaked at $23.5M in Q2 2025. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Jacobs Levy Equity Management held 199,800 shares of Pacira BioSciences worth $5.07M as of Q2 2026.
Jacobs Levy Equity Management bought 11,614 Pacira BioSciences shares in Q2 2026, an estimated $275K.
Pacira BioSciences made up 0.02% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #428 holding.
Jacobs Levy Equity Management first reported a position in Pacira BioSciences in Q3 2017 and has held it in 17 quarters since.
Jacobs Levy Equity Management's Pacira BioSciences position peaked at $23.5M in Q2 2025.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.